Key result
Abciximab improved outcomes in high-risk PCI patients but worsened outcomes in conservatively treated ACS patients, with an acceptable safety profile despite increased minor bleeding.
Why the study?
Does abciximab improve efficacy and safety outcomes in patients with acute coronary syndromes or undergoing percutaneous coronary intervention?
Population
Patients with acute coronary syndromes or those undergoing percutaneous coronary intervention from main…
Comparison
Abciximab vs Placebo
Design
Systematic_review
Authors
Loading...
Reserve abciximab for high-risk PCI; confirms strategy-specific efficacy with acceptable safety in ACS.
Systematic Review
Does abciximab improve efficacy and safety outcomes in patients with acute coronary syndromes or undergoing percutaneous coronary intervention?
Abciximab is beneficial for high-risk patients undergoing PCI but not for conservatively managed ACS, and carries an increased risk of minor bleeding and thrombocytopenia.
Tamhane et al. (2008) conducted a systematic review in Acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI). Abciximab vs. Placebo was evaluated on Efficacy and safety end points (major and minor bleeding, thrombocytopenia). Abciximab improved outcomes in high-risk PCI patients but worsened outcomes in conservatively treated ACS patients, with an acceptable safety profile despite increased minor bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: